Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

One daysingle sourceOne outlet reported this, once - no second voice in this corpus.

All 1 reports on Wed, 5 August 2026

What it is about

Jeff Macdonald Heath Lukatch John Markels Andrew Guggenhime Patrick Ryan Moncef Slaoui Group A Streptococcus Nasdaq Group A Streptococcus In Healthy Adults Corporate Affairs Research Development R D Expenses Program Milestones Glaxosmithkline Terms Of Service Company Initiated Phase Drug Administration Exchange Commission Group A Strep Manila, Manila, Philippines

Who published it, and when

How it spread - 1 original report

Wed, 5 August 2026
1 report
- manilatimes.net20:09first to report
  Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
  Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027